I.J.M. Beresford

GSK189254, a Novel H3 Receptor Antagonist That Binds to Histamine H3 Receptors in Alzheimer’s Disease Brain and Improves Cognitive Performance in Preclinical Models

Andrew D. Medhurst, A.R. Atkins, I.J.M. Beresford et al. · Journal of Pharmacology and Experimental Therapeutics · 2007 · 301 citations

Medicine, Medicinal Chemistry, Pharmacology +13

Investigation into species variants in tachykinin NK₁ receptors by use of the non‐peptide antagonist, CP‐96,345

I.J.M. Beresford, P.J. Birch, R.M. Hagan et al. · British Journal of Pharmacology · 1991 · 220 citations · Full text

Medicine, Pharmacology, Comparative Pharmacology +13

Pharmacological characterization of human recombinant melatonin mt₁ and MT₂ receptors

Christopher R. Browning, I.J.M. Beresford, Neil J. Fraser et al. · British Journal of Pharmacology · 2000 · 132 citations · Full text

Medicine, Endocrinology, Pharmacology +13

A Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of the H<sub>3</sub> Receptor Antagonist, GSK239512 as a Monotherapy in Subjects with Mild-to-Moderate Alzheimer’s Disease

Richard Grove, Conn Harrington, Andreas Mahler et al. · Current Alzheimer Research · 2014 · 109 citations

Medicine, Pharmacology, Pharmacotherapy +17

Receptor-selective, peptidase-resistant agonists at neurokinin NK-1 and NK-2 receptors: New tools for investigating neurokinin function

R.M. Hagan, S.J. Ireland, Christopher Jordan et al. · Neuropeptides · 1991 · 108 citations

Medicine, Neuroscience, Pharmacology +14